Updated project metadata. While aberrant protein glycosylation is a recognised characteristic of human cancers, advances in glycoanalytics continue to discover new associations between glycoproteins and tumourigenesis. This glycomics-centric study investigates a possible link between protein paucimannosylation, an under-studied class of human N-glycosylation [Man1-3GlcNAc2Fuc0-1] and human cancers. The distribution of paucimannosidic glycans (PMGs) within the N-glycome of 34 cancer cell lines and 133 tissue samples spanning 11 prevalent cancer types and matching non-cancerous specimens were accurately determined from 467 PGC-LC-MS/MS datasets collected over a decade within our laboratories. PMGs, particularly the α1,6-fucosylated bi- and tri-mannosylated N-glycans, were prominent features of 29 cancer cell lines, but the PMG level varied dramatically across and within the investigated cancer types (1.0%-50.2%). Analyses of paired (tumour/non-tumour) and stage-stratified tissue cohorts demonstrated that PMGs are significantly enriched in tumours from four cancer types including liver and colorectal cancer and increase with prostate cancer and chronic lymphocytic leukaemia progression. Cancer cell surface expression of paucimannosidic proteins was demonstrated using immunofluorescence while biosynthetic involvement of β-hexosaminidase was indicated by quantitative proteomics. The intriguing association between protein paucimannosylation and human cancers reported here warrants further exploration to detail the biosynthesis, cellular location(s), protein carriers and functions of paucimannosylation in tumourigenesis and metastasis.